Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results Up to 1-Year from Two Phase 3 Studies

Bimzelx (bimekizumab-bkzx) - UCB

Lihi Eder; Philip Mease; Iain B. McInnes; M. Elaine Husni; Mitsumasa Kishimoto; Barbara Ink; Rajan Bajracharya; Jason Coarse; Fabian Proft

May 7, 2026